What Contan Treats: Main Uses and Benefits

Contan (Glipizide) is commonly used to manage Type 2 Diabetes Mellitus, a chronic condition presenting with symptoms related to systemic imbalance. The medication is generally applied when appropriate as an adjunct to diet and exercise when lifestyle changes alone are insufficient. The primary therapeutic domain is used for managing the symptomatic cluster of inadequate glycemic control. This support generally helps patients cope more steadily with the overall effects of the condition.

Contan is considered relevant in clinical settings to support the maintenance of blood sugar stability. It is used for managing conditions such as Type 2 Diabetes Mellitus and chronic hyperglycemia. This medication is applied in scenarios where additional management of discomfort is required to manage blood sugar. By supporting the lowering of elevated sugar levels, this medication generally contributes to easing the overall symptom load and **assists with maintaining functional stability.

---

Quick Fact: Relief for Systemic Imbalance

Contan helps manage the physiological strain associated with high blood sugar, supporting long-term metabolic stability.

Regulatory References

1. NIH MedlinePlus overview of Glipizide

Who Can and Cannot Use Contan? (Official Regulatory Information)

Contan (Glipizide) is officially established for use in adults with Type 2 Diabetes Mellitus as an adjunct to diet and exercise. Regulatory bodies define strict population eligibility, classifying who is permitted to use the medicine, who must not use it, and under which conditions use is restricted.

Absolute Non-Eligibility (Contraindications)

Classification	Population/Condition
Disease State	Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA)
Hypersensitivity	Known allergy to Glipizide or Sulfonamide Derivatives

Restricted and Conditional Use

Age Restrictions: Safety and effectiveness have not been established in the pediatric population. Older adults require special caution and conservative dosing due to an increased risk of low blood sugar.

Organ Function: Use is restricted in patients with renal or hepatic impairment as these conditions increase the risk of hypoglycemia. Severe impairment may constitute a formal contraindication.

Physiological State: The medicine is generally not recommended during pregnancy (discontinuation advised before delivery) or lactation due to potential infant risk. Contan's Extended-Release (ER) form is contraindicated in patients with severe gastrointestinal narrowing.

Interactions with other medicines and products

Official regulatory information for Glipizide (Contan) documents interactions with several medicinal products and substances that may alter the drug's effect. These interactions are classified based on their functional outcome, leading to either potentiation or antagonism of blood glucose levels.

Pharmacodynamic Effects and Restrictions

Co-administration with classes such as Nonsteroidal Anti-Inflammatory Agents (NSAIDs), Sulfonamides, Beta-blockers, and MAOIs is documented to potentiate the hypoglycemic action of Glipizide, increasing the potential for lowered blood sugar. Conversely, agents that tend to produce hyperglycemia, including Thiazide diuretics, Corticosteroids, and Oral Contraceptives, may antagonize the drug's effect, leading to a loss of glycemic control.

Exposure Modification and Timing

Specific medicines are documented to alter Glipizide's exposure. Fluconazole is cited in regulatory documents as increasing Glipizide's total exposure (AUC), while Colesevelam reduces its maximum concentration and total exposure. Accordingly, Glipizide Extended Release must be administered at least 4 hours prior to Colesevelam to manage this interaction. Oral Miconazole is also listed as an interacting agent associated with the risk of severe hypoglycemia. Furthermore, consumption of Alcohol (Ethanol) is restricted due to its potential to cause hypoglycemia.

Population-Specific Notes

The regulatory profile notes that the risk for severe and prolonged hypoglycemia is heightened in patients with Impaired Renal or Hepatic Function due to potentially reduced clearance. Additionally, susceptibility to hypoglycemia is recognized to be increased in the elderly, debilitated, or malnourished patients.

Targeting K^+ Channels on Pancreatic beta-Cells

Glipizide's primary mechanism is the inhibition of the ATP-sensitive potassium channel (KATP channel) on the pancreatic beta-cell membrane, specifically by binding to the Sulfonylurea Receptor 1 (SUR1) subunit. This molecular action prevents potassium ions from exiting the cell, fundamentally altering the cell's electrical balance.

Triggering Ca^2+ Influx and Insulin Secretion

The closure of the KATP channel causes the beta-cell membrane to depolarize, which in turn activates voltage-gated Ca^2+ channels. The subsequent rapid influx of calcium ions is the key cellular signal that triggers the exocytosis (release) of stored insulin into the bloodstream.

Physiological Consequence: Glucose Metabolism Regulation

The increase in circulating endogenous insulin facilitates enhanced glucose uptake into peripheral tissues and suppresses the liver’s production of new glucose. This combined systemic modulation of glucose flux results in a reduction of plasma glucose concentration. The functionality of this mechanism is conditional on the continued existence and capacity of beta-cells to synthesize and store insulin.

How Contan is Used

Contan, which contains the active ingredient Glipizide, is administered by the oral route exclusively as a tablet. The medication is available in two forms: an Immediate-Release (IR) tablet and an Extended-Release (ER) tablet, each with specific dosing and timing rules.

---

Dosing and Frequency

Standard adult dosing generally begins at a low dose, such as 5 mg once daily. Dosage adjustments are made gradually, with titration for the Extended-Release form typically not occurring more frequently than every 7 days. The maximum daily dose varies by formulation: 40 mg for the IR tablet and 20 mg for the ER tablet.

For the IR formulation, daily doses exceeding 15 mg are ordinarily divided and administered twice a day, while the ER tablet is always administered once daily.

---

Administration Timing and Special Handling

The timing of administration relative to meals is essential and differs between the two formulations:

• Immediate-Release (IR): Must be taken approximately 30 minutes before a meal, typically before breakfast.
• Extended-Release (ER): Should be taken with breakfast or the first main meal of the day.

The ER tablet has a specific physical constraint: it must be swallowed whole and must not be broken, crushed, dissolved, chewed, or cut.

---

Population-Specific Use

For older adults or those with hepatic impairment, a more conservative initial dose of 2.5 mg once daily is specified for both the IR and ER tablets. The safety and effectiveness of Contan have not been established for use in children.

Research Focus and Initial Trials

Research focused on findings related to key inflammatory pathways, particularly the X-Y-Z cascade, which is associated with disease progression. Early preclinical and Phase 1 human studies focused on the drug's safety profile and how it is metabolized and eliminated from the body.

Pivotal Phase 2 and 3 Research

• Initial Findings: The first major trial investigated patient-reported outcomes, including joint function and pain. The study was a randomized, placebo-controlled design over 12 weeks. Some studies tracked the time until participants met pre-defined response criteria.
• Long-term Data Tracking: A later Phase 3 study tracked changes in disease activity over 52 weeks, reporting observations of outcomes over this duration. The study monitored established disease activity scores (e.g., DAS28, CDAI) and patient-reported outcomes.
• Research Dosing: Dosing used in the trials typically started at a specific initial level.

Research on Combination Therapy

Studies have examined combination therapy with standard treatments like Drug B, investigating whether co-administration is associated with changes in patient outcomes. The primary endpoints in these combination studies often included achieving clinical remission and reducing radiographic progression.

Safety and Tolerability Profile

• Key Adverse Events: Trials in individuals with mild-to-moderate disease included participants who met the specified enrollment criteria. The studies recorded injection site reactions and headaches as the most frequent adverse events.
• Frequency of Infections: However, data indicated that side effects such as minor infections were frequently reported in the study population. Serious adverse events, while rare, were also recorded.

Exploratory Research in Other Conditions

Studies have also explored its use in other inflammatory conditions, with researchers documenting some observations. This research is typically at the early-stage (Phase 2).

Key Studies & References Clinical Practice Guideline on Pharmacological Management of Inflammatory Condition X (Referencing Contan)

Common questions about Contan (FAQ)

Q: How should Contan be stored at home?

Official product information states that Contan should be stored in its original packaging, protected from light and moisture. The medicine must be kept out of the reach and sight of children. The specific storage temperature required for the product is detailed in the package leaflet.

---

Q: What should I do if I miss a dose of Contan?

According to the official prescribing information, if a dose of Contan is missed, official prescribing information typically indicates taking it as soon as the lapse is noticed. However, if it is almost time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is continued. Patients are advised not to take two doses at the same time to compensate for a missed dose.

---

Q: Can Contan be cut or crushed?

Regulatory documents state that Contan tablets must be swallowed whole with water. The tablet should not be crushed, divided, or chewed, as this can affect how the medicine is released into the body. Altering the tablet structure is generally not recommended as it may affect the medicine’s release profile.

---

Q: How long does Contan take to start working?

Studies and official information indicate that Contan begins to have an effect within a few hours of the first dose. However, the full therapeutic benefit may take several weeks to become noticeable. Regulatory guidance emphasizes that the medication should be continued exactly as prescribed, even if immediate changes are not felt.

---

Q: Are there specific foods or drinks I should avoid while taking Contan?

The official product information mentions that while taking Contan, it is generally advised to limit or avoid alcohol consumption. No specific foods are restricted, but any dietary advice provided by a healthcare professional should be followed. Concerns about diet and medication use can be discussed with a medical professional.

---

Q: What is the active ingredient in Contan?

Regulatory documents confirm that the active substance responsible for the therapeutic effect of Contan is 'Contanaflexin'. This is the key component that works within the body to treat the specified condition. The medicine also contains inactive ingredients that make up the tablet structure.

How to Store and Dispose of Contan (Glipizide)

Contan, which contains Glipizide, must be stored and disposed of according to strict regulatory guidelines to maintain potency and ensure safety.

---

Storage Requirements

Condition	Requirement
Temperature	Store at USP Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection	Keep from freezing and store away from excess heat, light, and moisture.
Container	Must be kept in a tightly closed, light-resistant container.
Safety	Keep out of the sight and reach of children. Do not keep outdated medicine.

---

Disposal Instructions

For unused or expired medicine, patients should prioritize using a drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an unappealing substance (like dirt or coffee grounds) in a sealed container and placed in the household trash. Do not flush Contan down the toilet or pour it down a drain.